Physician profile
Brian S Aprill
NPI 1588659023
$6,104.10
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,070 · 2020: $550 · 2021: $404 · 2022: $380 · 2023: $501 · 2024: $200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $701.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $701.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,092.63 | 2019-2022 | |
| Lilly USA, LLC | $708.63 | 2019-2023 | Mounjaro |
| Novo Nordisk INC | $650.60 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $473.11 | 2019-2023 | |
| Amgen INC. | $458.53 | 2019-2020 | |
| Abbott Laboratories | $430.37 | 2019-2023 | Freestyle Libre 3 |
| Mannkind Corporation | $390.54 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $216.83 | 2019-2022 | |
| Insulet Corporation | $176.28 | 2019 | |
| Corcept Therapeutics | $159.34 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $153.43 | 2019 | |
| Dexcom, INC. | $123.75 | 2023-2024 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Valeritas, INC. | $119.23 | 2019 | |
| Horizon Therapeutics Plc | $110.66 | 2019-2023 | Tepezza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $102.37 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $93.63 | 2019 | |
| Cequr Corporation | $92.82 | 2024 | Cequr Simplicity |
| Pfizer INC. | $87.79 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $85.51 | 2019 | |
| Companion Medical, INC. | $56.58 | 2019 | |
| Medtronic Minimed, INC. | $54.32 | 2019 | |
| Abbvie INC. | $42.23 | 2019 | |
| Tandem Diabetes Care, INC. | $34.44 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $33.91 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $30.96 | 2019 | |
| Senseonics, Incorporated | $26.00 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $20.32 | 2019 | |
| Lifescan, INC. | $17.56 | 2021 | |
| Novartis Pharmaceuticals Corporation | $17.02 | 2019 | |
| Radius Health, INC. | $16.45 | 2019 | |
| Alexion Pharmaceuticals, INC. | $14.57 | 2019 | |
| Eisai INC. | $13.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Aprill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.